Breaking News, Collaborations & Alliances

Horizon, Otsuka in Development and Commercialization Pact

To perform in-vitro cell line screening of OPDC candidates

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Horizon Discovery Group’s newly aquired CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidates. Horizon will receive $835,000 for the work to be substantially completed this year.   Horizon CombinatoRx provides access to the cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations.    ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters